Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Pexidartinib & Tenosynovial giant cell tumor (TGCT)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

The US FDA approves only Pexidartinib; however, the European Medicines Agency has not approved it due to an uncertain risk-benefit ratio.
Spierenburg et al. 2022 Expert Opinion on Therapeutic Targets 26(4): 333-345

ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT)
Tap 2020 Future Oncology 16: 1875–1878
Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy
Palmerini et al. 2020 Exp Rev Anticancer Therapy 20: 441-445
Review
Pexidartinib vs placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase III trial
Tap et al. 2019 The Lancet 394: 478-487
Pexidartinib: First approved systemic therapy for pts with tenosynovial giant cell tumor
Gelderblom & van de Sande 2020
Review
Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches
Spierenburg et al. 2022 Expert Opinion on Therapeutic Targets 26(4): 333-345
Review

7/1/2026